Fig. 6

Biocompatibility of 7CZ nanomedicines in rats with ADR-induced nephrotic syndrome. a The levels of body weight were recorded in 8 days of post treatment (n = 5). The ratio of urinary protein to creatinine (b), serum CRE (c), BUN (d), ALT (e) and AST (f) after 7CZ nanomedicines i.p. injection (n = 5). g H&E staining of rat heart, liver, spleen, and lung, after treatment with 7CZ nanomedicines or normal saline for 8 days. The 7CZ nanomedicines group represents the ADR-induced NS treated with 0.1 mg/kg 7CZ nanomedicines every other day. Data are presented as mean ± SD, one-way ANOVA, ns, non-significance, *P < 0.05, **P < 0.01; ***P < 0.001, ****P < 0.0001, not significant, vs. ADR group